Arcellx, INC Form 4 insider transactions

Director Jill Carroll reports the disposition of Arcellx, Inc. shares and options following the company's acquisition by Gilead Sciences.

Arcellx, Inc. reports completion of its merger with Gilead Sciences, Inc., detailing executive stock option conversions and beneficial ownership changes.

Director Olivia C. Ware of Arcellx, Inc. has reported transactions related to the company's merger with Gilead Sciences, Inc., detailing the conversion of stock options.

Arcellx, Inc. Director Kavita Patel has reported transactions related to stock options following the company's merger with Gilead Sciences, Inc.

Arcellx, Inc. Director Kristin Myers has reported transactions related to the company's merger with Gilead Sciences, Inc., detailing the conversion of stock options.

Arcellx, Inc. Director David Lubner has reported changes in beneficial ownership of company stock and stock options following a merger with Gilead Sciences, Inc.

Andrew H. Galligan, a Director at Arcellx, Inc., reported transactions related to his beneficial ownership of common stock and stock options following the company's merger with Gilead Sciences.

Arcellx, Inc. Chief Financial Officer Michelle Gilson has filed a Form 4 detailing transactions related to the company's merger with Gilead Sciences, Inc.

Christopher Heery, Chief Medical Officer of Arcellx, Inc., has reported changes in beneficial ownership following the company's merger with Gilead Sciences, Inc.

Rami Elghandour, Director and Officer of Arcellx, Inc., filed a Form 4 detailing transactions related to the company's merger with Gilead Sciences, Inc.

Arcellx CFO Michelle Gilson exercised options to acquire 38,110 shares of common stock on April 15 and 16, 2026.

Arcellx Chief Financial Officer Michelle Gilson transferred 5,000 shares of common stock to a family charitable foundation, retaining voting and investment control.

Arcellx's President, CEO, and Chairman, Rami Elghandour, transferred 101,164 shares of common stock to a family charitable foundation for no consideration.

Arcellx CEO Rami Elghandour reported the sale of 89,916 shares of common stock to cover tax withholding obligations related to RSU vesting, while also disclosing direct and indirect holdings.

Arcellx's Chief Financial Officer, Michelle Gilson, reported the sale of 11,219 common shares to cover tax withholding obligations related to restricted stock unit vesting.

Arcellx's Chief Financial Officer, Michelle Gilson, sold 8,384 shares of common stock to cover tax withholding obligations related to vested restricted stock units.

Arcellx, Inc. CEO Rami Elghandour transferred 198,000 shares of common stock to a spousal lifetime access non-grantor trust.

Arcellx CEO Rami Elghandour's spouse transferred 218,500 shares of common stock to a spousal lifetime access non-grantor trust.

Arcellx Director David Charles Lubner exercised stock options and subsequently sold 6,000 shares of common stock for a significant profit under a pre-arranged trading plan.

Arcellx's Chief Medical Officer, Christopher Heery, reported the vesting of restricted stock units and a subsequent sale of shares to cover tax liabilities.

Arcellx Chief Medical Officer Christopher Heery sold 7,437 shares of common stock to cover tax obligations related to RSU vesting.

Arcellx's Chief Medical Officer, Christopher Heery, sold 6,131 shares of common stock to cover tax withholding obligations related to RSU vesting.

Arcellx Chief Medical Officer Christopher Heery reported the acquisition of common stock through the vesting of restricted stock units and an employee stock purchase plan.

Arcellx, Inc. Director and Officer Rami Elghandour reported the acquisition of 164,548 common shares through the vesting and conversion of restricted stock units, alongside a new RSU grant.

Arcellx's Chief Financial Officer, Michelle Gilson, filed a Form 4 detailing future acquisitions of common stock through the vesting of Restricted Stock Units under a Rule 10b5-1 plan.

Arcellx Chief Medical Officer Christopher Heery sold 340 shares of common stock for $90 per share on November 17, 2025, under a pre-arranged 10b5-1 trading plan.

Arcellx, Inc.'s Chief Financial Officer, Michelle Gilson, sold 5,364 shares of common stock for approximately $91.04 per share under a pre-arranged 10b5-1 trading plan.

Arcellx Chief Financial Officer Michelle Gilson sold 5,946 shares of common stock in early October 2025, executed under a pre-arranged Rule 10b5-1 trading plan.

Arcellx Chief Medical Officer Christopher Heery sold a total of 21,034 shares of common stock on September 30, 2025, under a pre-arranged 10b5-1 trading plan.

Arcellx Chief Medical Officer Christopher Heery reported the sale of 73 common shares for $80.16 each, executed under a Rule 10b5-1 trading plan.